Keywords
minimal cognitive impairment
myalgic encephalomyelitis/chronic fatigue syndrome
melatonin
How to Cite
Abstract
Melatonin is particularly effective in reducing symptomatology of SARS-CoV-2 infection due to its roles as an antioxidant, anti-inflammatory, and immunomodulatory agent. Melatonin is also an effective chronobiotic/hypnotic medication for treating delirium and restoring circadian imbalance in COVID patients in the intensive care unit. Furthermore, as a cytoprotectant, melatonin helps to prevent a number of comorbidities of COVID-19, such as diabetes, metabolic syndrome, and ischemic and non-ischemic cardiovascular diseases. The clinical sequelae and symptoms of many patients with COVID-19 can persist for months beyond the acute stage of SARS-CoV-2 infection, the so-called “long COVID”. Melatonin, as a neuroprotective agent, emerges as an excellent agent to control cognitive impairment ("brain fog") and pain in myalgic encephalomyelitis/chronic fatigue syndrome, like that documented in prolonged COVID.
References
Cardinali D. P. (2019a). Melatonin: Clinical Perspectives in Neurodegeneration. Frontiers in endocrinology, 10, 480. https://doi.org/10.3389/fendo.2019.00480
Cardinali, D. P. (2019b). Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection? Melatonin Research, 2(2), 106–132. https://doi.org/10.32794/mr11250025
Cardinali, D. P., Brown, G. M., y Pandi-Perumal, S. R. (2020). Can Melatonin Be a Potential "Silver Bullet" in Treating COVID-19 Patients?. Diseases (Basel, Switzerland), 8(4), 44. https://doi.org/10.3390/diseases8040044
Cardinali, D. P., Brown, G. M. y Pandi-Perumal, S. R. (2022). Melatonin's Benefits and Risks as a Therapy for Sleep Disturbances in the Elderly: Current Insights. Nature and science of sleep, 14, 1843–1855. https://doi.org/10.2147/NSS.S380465
Citera, G., Arias, M. A., Maldonado-Cocco, J. A., Lázaro, M. A., Rosemffet, M. G., Brusco, L. I., Scheines, E. J. y Cardinalli, D. P. (2000). The effect of melatonin in patients with fibromyalgia: a pilot study. Clinical rheumatology, 19(1), 9–13. https://doi.org/10.1007/s100670050003
Hemati, K., Amini Kadijani, A., Sayehmiri, F., Mehrzadi, S., Zabihiyeganeh, M., Hosseinzadeh, A. y Mirzaei, A. (2020). Melatonin in the treatment of fibromyalgia symptoms: A systematic review. Complementary therapies in clinical practice, 38, 101072. https://doi.org/10.1016/j.ctcp.2019.101072
Reiter, R. J., Ma, Q. y Sharma, R. (2020). Treatment of ebola and other infectious diseases: melatonin “goes viral.” Melatonin Research, 3(1), 43–57. https://doi.org/10.32794/mr11250047
Reiter, R. J., Sharma, R., Simko, F., Dominguez-Rodriguez, A., Tesarik, J., Neel, R. L., Slominski, A. T., Kleszczynski, K., Martin-Gimenez, V. M., Manucha, W. y Cardinali, D. P. (2022). Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection. Cellular and molecular life sciences: CMLS, 79(3), 143. https://doi.org/10.1007/s00018-021-04102-3
Sumsuzzman, D. M., Choi, J., Jin, Y. y Hong, Y. (2021). Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer's disease and insomnia: A systematic review and meta-analysis of randomized controlled trials. Neuroscience and biobehavioral reviews, 127, 459–473. https://doi.org/10.1016/j.neubiorev.2021.04.034
Taquet, M., Sillett, R., Zhu, L., Mendel, J., Camplisson, I., Dercon, Q. y Harrison, P. J. (2022). Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. The lancet. Psychiatry, 9(10), 815–827. https://doi.org/10.1016/S2215-0366(22)00260-7
Xu, L., Yu, H., Sun, H., Hu, B. y Geng, Y. (2020). Dietary Melatonin Therapy Alleviates the Lamina Cribrosa Damages in Patients with Mild Cognitive Impairments: A Double-Blinded, Randomized Controlled Study. Medical science monitor: international medical journal of experimental and clinical research, 26, e923232. https://doi.org/10.12659/MSM.923232
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2023 Pinelatinoamericana